All In Biotech

Drug Trial Radar · NCT06263244

Specifying the Anti-inflammatory Effects of Ziltivekimab

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

May 3, 2024

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Sponsor type
Academic, hospital or other
First posted
Feb 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

Conditions

  • Atherosclerosis
  • Inflammation

Interventions

  • ZiltivekimabDrug

    Monoclonal antibody targeting IL-6

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TBRmax coronary arteriesTime frame: 5.5 months
  2. monocyte activation marker protein expressionTime frame: 5.5 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amsterdam UMC, location AMC

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.